KR900004708A - 카르바진산 유도체, 그 제조방법 및 용도 - Google Patents

카르바진산 유도체, 그 제조방법 및 용도 Download PDF

Info

Publication number
KR900004708A
KR900004708A KR1019890013045A KR890013045A KR900004708A KR 900004708 A KR900004708 A KR 900004708A KR 1019890013045 A KR1019890013045 A KR 1019890013045A KR 890013045 A KR890013045 A KR 890013045A KR 900004708 A KR900004708 A KR 900004708A
Authority
KR
South Korea
Prior art keywords
substituted
group
salt
halogen atoms
acid derivative
Prior art date
Application number
KR1019890013045A
Other languages
English (en)
Inventor
다까시 소오다
히또시 이께다
유우 모모세
Original Assignee
우메모또 요시마사
다께다야꾸힝고오교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 우메모또 요시마사, 다께다야꾸힝고오교 가부시끼가이샤 filed Critical 우메모또 요시마사
Publication of KR900004708A publication Critical patent/KR900004708A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C281/00—Derivatives of carbonic acid containing functional groups covered by groups C07C269/00 - C07C279/00 in which at least one nitrogen atom of these functional groups is further bound to another nitrogen atom not being part of a nitro or nitroso group
    • C07C281/02—Compounds containing any of the groups, e.g. carbazates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/135—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)

Abstract

내용 없음

Description

카르바진산 유도체, 그 제조방법 및 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (15)

  1. 하기식의 카르바진산 유도체 또는 그염.
    R1-N=CH-NHNH-R2
    (상기 식에서 R1은 헤테로고리기이고 R2는 에스테르화 카르복실기임)
  2. 제1항에 있어서, R1이 분자량 60-300의 헤테로고리기인 카르바진산 유도체 또는 그염.
  3. 제1항에 있어서, 헤테로고리기가 (i)(a) 1∼4개의 할로겐원자로 치환될 수 있는 C1-C10직쇄, 분지쇄 또는 고리형 알킬기, (b) 할로겐, (c) 히드록실, C1∼4알콕시, 1∼4개의 할로겐원자로 치환될 수 있는 페닐-C1∼4알킬옥시, C2-4알카노일 옥시, 또는 1∼4개의 할로겐원자로 치환될 수 있는 C6-10아릴옥시, (d) 니트로, (e) C1-10알킬카르보닐, 또는 아릴기가 1∼4개의 할로겐원자 및 C1∼4알콕시로 치환될 수 있는 C6-10알릴카르보닐, (f) 아실기가 상기 (e)에서 정의된 바와같은 아실아미노, (g) 1∼4개의 C1-C10알킬, C7-10아랄킬 및 술로닐기로 치환될 수 있는 아미노, 또는 (h) 1∼4개의 할로겐원자로 치환될 수 있는 C1-C10직쇄, 분지쇄 또는 고리형 알킬티오 또는 C7∼C12아랄킬티오중 1∼4개로 치환될 수 있는 C6∼C14아릴, (ii) 상기 (i)에서 언급된 (a)∼(h)의 기중 1∼4개로 치환될 수 있는, 질소, 산소 및 황원자 중 적어도 하나를 함유하는 5- 또는 6-원 포화 또는 불포화 헤테로고리기 또는 그 축합 헤테로고리기, (ⅲ) 1∼4개의 할로겐원자로 치환될 수 있는 C1-C10직쇄, 분지쇄 또는 고리형 알킬기, (ⅳ) 할로겐원자, (ⅴ) 히드록실, C1∼4알콕시, 1∼4개의 할로겐원자로 치환될 수 있는 페닐-C1∼4알킬옥시, C1∼4알카노일옥시, 또는 1∼4개의 할로겐원자로 치환될 수 있는 C6-10아릴옥시, (ⅵ) 니트로, (ⅶ) C1-10알킬카르보닐, 또는 아릴기가 1∼4개의 할로겐원자 및 C1∼4알콕시로 치환될 수 있는 C6-10아릴카르보닐, (ⅷ) 아실기가 상기 (ⅶ)에서 정의된 바와같은 아실아미노, (ⅸ) C1-10알킬, C7-12아랄킬 및 술포닐기 중 1∼2개로 치환될 수 있는 아미노, (ⅹ) 1∼4개의 할로겐원자로 치환될 수 있는 C1-C10직쇄, 분지쇄 또는 고리형 알킬티오기 및 (xi) 1∼4개의 할로겐원자로 치환될 수 있는 C7-C12알랄킬티오 중에서 선택되는 1∼4개의 같거나 다른 치환기로 치환될 수 있는, 1∼4개의 질소, 산소 및 황을 고리-형성 헤테로원자로서 함유하는 5- 또는 6-원 불포화 헤테로고리 또는 그 축합고리인 카르바진산 유도체 또는 그염.
  4. 제1항에 있어서, 헤테로고리가 1∼2개의 (ⅰ) C1∼C4알킬기 및 (ⅱ) C3∼C6시클로알킬기 또는 1∼4개의 할로겐원자로 치환될 수 있는 페닐-C1-3알킬옥시기로 치환될 수 있는 C6∼C10아릴기로 치환될 수 있는 티아졸릴기인 카르보진산 유도체 또는 그염.
  5. 제1항에 있어서, 에스테르화 카르복실기가 식 -COOR2(식중에서 R28는 에스테르잔기 임)의 기인카르바진산 유도체 또는 그염.
  6. 제5항에 있어서, 에스테르잔기가 할로겐원자 및 C1∼C4알콕시중 1∼3개로 치환될 수 있는 C1∼C10알킬, C6∼C14아릴 또는 페닐 -C1∼C4알킬기인 카르바진산 유도체 또는 그염.
  7. 제5항에 있어서, 에스테르잔기가 C1∼C4알킬 또는 C6∼C10아릴기인 카르바진산 유도체 또는 그염.
  8. 제1항에 있어서, 염이 약학적으로 허용되는 염인 카르바진산 유도체 또는 그염.
  9. 제1항에 있어서, 하기식의 화합물 또는 약학적으로 허용되는 그염인 카르바진산 유도체 또는 그염.
    (상기식에서 R2b는 C1∼C4알킬기 또는 C6∼C10아릴기임)
  10. 제1항에 있어서, 하기식의 화합물 또는 약학적으로 허용되는 그염인 카르바진산 유도체 또는 그염.
    (상기식에서 R2b는 C1∼C4알킬기 또는 C6∼C10아릴기임)
  11. 제1항에 있어서, tert-부틸-3-[4-[4-(4-클로로벤질옥시)페닐]-2-티아졸릴 이미노메틸]카르바제이트인 가르바진산 유도체 또는 그염.
  12. 제1항에 있어서, 에틸 3-[4-(4-시클로헥실페닐)-2-티아졸릴이미노메틸]카르바제이트인 카르바진산 유도체 또는 그염.
  13. 제1항에 있어서, R1이 시클로헥실 페닐 또는 시클로벤질옥시페닐로 치환될 수 있는 티아졸릴기인 카르바진산 유도체 또는 그염.
  14. 식 R1-N=CH-OR3(식중에서 R1은 헤테로고리기이고 R3는 저급알킬기임)로 표시되는 화합물을 카르바진산 에스테르 또는 그염과 반응시키는 것을 특징으로 하는 식 R1-N=CH-NHNH-R2(식중 R1은 상기에 정의된 바와같고, R2는 에스테르화 카르복실기 임)의 카르바진산 유도체 또는 그의 제조방법.
  15. 유효량의 하기식으로 표시되는 카르바진산 유도체 또는 약학적으로 허용되는 그염을 적당한 담체(들)와 함께 함유하는 AGE-형성억제제.
    R-N=CH-NHNH-R2
    (상기식에서 R은 헤테로고리 또는 아릴기이고, R2는 에스테르화 카르복실기임)
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890013045A 1988-09-08 1989-09-08 카르바진산 유도체, 그 제조방법 및 용도 KR900004708A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP22519888 1988-09-08
JP63-225198 1988-09-08
JP1-173369 1989-07-04
JP1173369A JP2817219B2 (ja) 1988-09-08 1989-07-04 カルバジン酸誘導体、その製造法及び製剤

Publications (1)

Publication Number Publication Date
KR900004708A true KR900004708A (ko) 1990-04-12

Family

ID=26495371

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890013045A KR900004708A (ko) 1988-09-08 1989-09-08 카르바진산 유도체, 그 제조방법 및 용도

Country Status (4)

Country Link
US (1) US5240950A (ko)
EP (1) EP0359112A3 (ko)
JP (1) JP2817219B2 (ko)
KR (1) KR900004708A (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114943A (en) * 1984-03-19 1992-05-19 The Rockefeller University Amino-substituted pyrimidines, derivatives and methods of use therefor
US5514676A (en) * 1984-03-19 1996-05-07 The Rockefeller University Amino-benzoic acids and derivatives, and methods of use
US6197806B1 (en) 1995-12-20 2001-03-06 Nippon Zoki Pharmaceutical Co., Ltd. Eliminating agent for activated oxygen and free radicals
KR100478181B1 (ko) 1998-08-24 2005-03-23 토카이 유니버시티 에듀케이셔널시스템 카르보닐 스트레스상태 개선제 및 복막투석액
US6121300A (en) 1998-11-10 2000-09-19 Wagle; Dilip R. Reversing advanced glycosylation cross-links using heterocyclic-substituted thiazolium salts
AU754989B2 (en) 1998-11-16 2002-11-28 Nippon Zoki Pharmaceutical Co., Ltd. A therapeutic agent for intractable vasculitis
JP4711523B2 (ja) 2001-02-13 2011-06-29 日本臓器製薬株式会社 低アルブミン血症改善剤
PT1243581E (pt) * 2001-03-21 2005-11-30 Torrent Pharmaceuticals Ltd Compostos de piridinio uteis no tratamento de doencas relacionadas com age
EP3325452B1 (en) * 2015-07-24 2022-03-30 INSERM (Institut National de la Santé et de la Recherche Médicale) Substituted hydrophobic benzene sulfonamide thiazole compounds for use in treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4758583A (en) * 1984-03-19 1988-07-19 The Rockefeller University Method and agents for inhibiting protein aging
AU600306B2 (en) * 1986-09-12 1990-08-09 Rockefeller University, The Methods and agents for removing advanced glycosylation endproducts

Also Published As

Publication number Publication date
JPH02167264A (ja) 1990-06-27
EP0359112A3 (en) 1990-08-29
EP0359112A2 (en) 1990-03-21
US5240950A (en) 1993-08-31
JP2817219B2 (ja) 1998-10-30

Similar Documents

Publication Publication Date Title
FI874451A (fi) Menetelmä lääkeaineina käyttökelpoisten dihydropyridiinin johdannaisten valmistamiseksi
KR840000494A (ko) 디하이드로피리딘의 제조방법
KR910000657A (ko) 옥사-또는 티아-졸린 유도체
AU657106B2 (en) Preparation and use of N-iodopropargyl oxycarbonyl amino acid esters and derivatives as antimicrobial agents
KR840006327A (ko) 페닐에틸아민 유도체의 제조방법
KR900004708A (ko) 카르바진산 유도체, 그 제조방법 및 용도
KR930703281A (ko) 벤즈옥사 축합 고리 화합물, 그의 제조방법 및 이를 함유한 약제 조성물
KR970015592A (ko) 13-치환 밀베마이신 5- 옥심 유도체, 그의 제조 방법 및 곤충 및 기타 해충에 대한 그의 용도
KR840006475A (ko) 나프탈렌 유도체의 제조방법
KR840006660A (ko) 6,7-디하이드로-8-(이미다졸-1-일)-5-메틸-1-옥소-1H,5H-벤조[ij]퀴놀리진-2-카르복실산 및 그 유도체의 제조방법
KR890011829A (ko) 디우레아 유도체 및 이의 제조방법
KR890009858A (ko) 카바조일 유도체
KR900003155A (ko) 항전신병특성을 가진 3-피페라지닐벤즈아졸 유도체
KR840006482A (ko) 디히드로피라졸로 [3,4-b]피리딘 유도체의 제조방법
KR880000450A (ko) 세팔로스포린 유도체의 제조방법
KR920018036A (ko) 티아졸리디논 및 옥사졸리디논 유도체, 그의 제조방법 및 혈관확장제로서의 용도
KR860002490A (ko) 2,3-디히드로벤조푸란-5-설폰아미드 유도체의 제조방법
KR870007153A (ko) 티아나프텐 유도체 및 이의 제조 방법
KR910016659A (ko) 키랄 나프탈린디카복실레이트
KR840001154A (ko) 1,2-디티올-3-일리덴 암모늄 유도체의 제조방법
KR880009906A (ko) 신규한 제초 화합물과 그 제조방법 및 이를 포함하는 제초조성물
KR880012545A (ko) 피롤알데히드 이의 제조방법 및 용도
KR900007821A (ko) Age-형성 억제제
KR860004040A (ko) 3,4-디아졸 유도체의 제조방법
KR920002526A (ko) 옥살산 유도체, 그의 제조방법 및 그를 함유한 식물 성장 조절제

Legal Events

Date Code Title Description
SUBM Surrender of laid-open application requested